Search - tctmd.com

Displaying 501 - 520 of 806

Sort: Relevancy | Date

Presentation TCT 2015

Stents in CTO: If I Get It Open, Will It Stay Open?

Presenter: Etsuo Tsuchikane, Gerald S. Werner, Sunao Nakamura

October 11, 2015

Presentation TCT 2015

Functional Risk Scoring: Fame 3 and Beyond

Presenter: Kevin J. Beatt, Craig R. Smith, William F. Fearon

October 11, 2015

Presentation TCT 2015

Are Risk Scores Practical and Useful to Differentiate PCI vs CABG?

Presenter: Kevin J. Beatt, Craig R. Smith, Davide Capodanno

October 11, 2015

Presentation TCT 2015

The SYNTAX Score in Clinical Practice: Promise and Pitfalls

Presenter: Kevin J. Beatt, Craig R. Smith, Philippe Généreux

October 11, 2015

Presentation TCT 2015

Critical Analysis of Current Guidelines on Multivessel Revascularization: Are They Up to Date?

Presenter: Kevin J. Beatt, Craig R. Smith, Marie-Claude Morice

October 11, 2015

Presentation TCT 2015

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Presenter: John A. Bittl, E. Magnus Ohman, Marco Valgimigli

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Presenter: John A. Bittl, E. Magnus Ohman, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Featured Lecture: New DAPT Duration Recommendations

Presenter: John A. Bittl, E. Magnus Ohman

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, Rajesh V Swaminathan

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

Presenter: Stephen G. Ellis, John A. Ormiston, Pieter C. Smits

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Presenter: Stephen G. Ellis, John A. Ormiston, Evald H. Christiansen

October 11, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Advertisement

Stents in CTO: If I Get It Open, Will It Stay Open?

Functional Risk Scoring: Fame 3 and Beyond

Are Risk Scores Practical and Useful to Differentiate PCI vs CABG?

The SYNTAX Score in Clinical Practice: Promise and Pitfalls

Critical Analysis of Current Guidelines on Multivessel Revascularization: Are They Up to Date?

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study

Featured Lecture: New DAPT Duration Recommendations

Lessons From the TAXUS Liberté/Prasugrel Substudy

Bare-Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Biomimetic Stents: Rationale and Current Clinical Results

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content